DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests whether adding the drug acalabrutinib to a CAR-T cell therapy (liso-cel) can improve outcomes for people with aggressive B-cell lymphoma that has returned or not responded to prior treatments. About 28 adults will receive the combination. The main goal is to see …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New hope for lymphoma patients: experimental drug shows promise
Disease control OngoingThis study tests a new drug called purinostat mesylate in about 74 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a type of blood cancer that has come back or not responded to prior treatments. The goal is to find a safe and effective dose and see how w…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Can stem cell dose boost recovery in tough lymphoma?
Disease control OngoingThis study looks at whether the number of stem cells given during a transplant affects recovery for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 59 adults who have already tried one chemotherapy and are eligible for a stem cell transplant will r…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Triple-Target CAR T-Cells take on Hard-to-Treat lymphomas
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Simple quiz may predict chemo danger for seniors with lymphoma
Knowledge-focused OngoingThis study looks at whether a self-administered geriatric assessment can help predict serious side effects from chemotherapy in people aged 60 and older with Non-Hodgkin lymphoma. About 200 participants will fill out a health questionnaire before starting treatment. The goal is t…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC